ESMO / ECC Conference Coverage
(BioPharma Dive) Oct 19, 2018 - Clovis Oncology, trailing PARP inhibitor rivals AstraZeneca and Tesaro, aims to jump ahead in a new market for the targeted therapies, announcing Friday positive early data for its drug Rubraca in metastatic castration-resistant prostate cancer.
(Novartis) Oct 19, 2018 - Novartis today announced presentation of a new analysis of Lutathera® (lutetium Lu 177 dotatate*) NETTER-1 data at the 2018 European Society for Medical Oncology (ESMO) congress examining the impact of Lutathera treatment on patients with low, medium or high liver tumor burden.
The data show that Lutathera...
There are no ESMO / ECC Conference Coverage OBR Green articles.